[Three Cases of Adenocarcinoma of the Advanced Esophago-Gastric Junction Confirmed as Pathological Complete Response Following Neoadjuvant Chemotherapyand Gastrectomy]

Gan To Kagaku Ryoho. 2016 Nov;43(12):1561-1563.
[Article in Japanese]

Abstract

Neoadjuvant chemotherapy(NAC)is thought to be effective to improve the outcomes in patients with adenocarcinoma of the esophago-gastric junction(AEG). We encountered 3 patients who were confirmed as having a pathological complete response following gastrectomy after NAC. The first patient had Siewert type II and clinical Stage III AEG, the second patient had Siewert type I and clinical Stage III AEG, while the third had Siewert type II and clinical Stage II AEG. Two patients received NAC with 2 courses of S-1 plus cisplatin, while the third patient received 2 courses of docetaxel, S-1, and cisplatin. All of the patients were treated with D2 gastrectomy after the NAC, and remain alive at more than 40 months after initial chemotherapy treatment without recurrence. We report the details of these 3 cases and review the literature.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnostic imaging
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / surgery
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Esophagogastric Junction / pathology*
  • Gastrectomy
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy*
  • Neoplasm Invasiveness
  • Stomach Neoplasms / diagnostic imaging
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents